SUNNYVALE, Calif., Jan. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. ( AMBS ), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced the launch of the Company's new website at www.amarantus.com .

"2012 was an exceptionally productive year for Amarantus with the acquisition of two diagnostic platforms to expand our pipeline, the addition of several industry experts to our advisory boards, and positive efficacy data in our Traumatic Brain Injury program," said Gerald Commissiong, President and CEO.  "We started 2013 demonstrating positive efficacy data for MANF in our Parkinson's program, and expect to make additional progress early this year with our diagnostic programs for chronic illnesses such as Parkinson's and Alzheimer's diseases."